1.	Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GBG 66, 2011-000553-23, NCT01426880
2.	A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO19391, NCT00448591
3.	Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001J2301, 2008-006556-21, NCT00876395
4.	A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO22223, 2008-006872-31, NCT00929240
5.	Phase III Randomized Study of Neoadjuvant Therapy Comprising Docetaxel, Fluorouracil, Epirubicin Hydrochloride, and Cyclophosphamide With Versus Without Bevacizumab in Patients With HER2-Negative Nonmetastatic Breast Cancer Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRCA-CCTC-WCTU-ARTemis, CCTC-WCTU-ARTemis, ISRCTN68502941, EUDRACT-2008-002322-11, EU-21017, MREC-08/H1102/104, NCT01093235
6.	Bevacizumab and Paclitaxel or Bevacizumab, Cyclophosphamide, and Capecitabine as First-Line Therapy in Treating Women With Locally Advanced, Recurrent, or Metastatic Breast Cancer Phase: Phase III Type: Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SAKK 24/09, SWS-SAKK-24-09, EU-21025, CDR0000669252, NCT01131195
7.	A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GBG 43, 2008-003997-17, NCT01200212
8.	Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12444, 2010-018501-10, NCT01234337
9.	A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO22998, 2010-020998-16, NCT01250379
10.	1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Arobase (GINECO-BR107), NCT01303679
11.	Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: Endostar B-02, CBCRT01, NCT01479036
12.	4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001JDE49, NCT01626222
13.	Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GO25632, 2011-005335-97, NCT01663727